Anticytokine autoantibodies in a patient with a heterozygous NFKB2 mutation - 05/04/18
![](/templates/common/images/mail.png)
Y.G. and A.P.W. were supported by Cancer Research UK and the National Institute for Health Research (NIHR) Experimental Cancer Medicine Centre, Southampton. K.A.R., W.R., S.V.P., and S.N.F. received support from the Southampton NIHR Wellcome Trust Clinical Research Facility. G.B.-M. was supported by grants from Universidad Nacional Autónoma de México – Dirección General de Asuntos del Personal Académico - Programa de Apoyo a Proyectos de Investigación e Innovación Tecnológica (UNAM-DGAPA-PAPIIT; grant nos. IN220815 and PIAPI-1642). R.D. was supported by the NIHR/Cambridge Biomedical Research Centre. |
|
Disclosure of potential conflict of interest: S. N. Faust's institution received consultancy fees from AstraZeneca, Cubist, Merck, and Pulmizime and grants from Pfizer, Sanofi, GSK, Novartis, Alios, Cubist, and Merck for other work. D. S. Kumararatne received consultancy fees from Shire Pharmaceticals and support for travel from CSL Behring for this work and is employed by University Hospital Cambridge. W. Rae received consultancy fees from Baxalta and travel fees from Shire Plc; his institution received grants from BioCryst Pharmaceuticals for other works. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 141 - N° 4
P. 1479 - avril 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?